Venetoclax
- Generic Name
- Venetoclax
- Brand Names
- Venclexta, Venclyxto
- Drug Type
- Small Molecule
- Chemical Formula
- C45H50ClN7O7S
- CAS Number
- 1257044-40-8
- Unique Ingredient Identifier
- N54AIC43PW
- Background
Venetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 . Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are important regulators of the apoptotic (programmed cell death) process , . Venetoclax is used to treat chronic lymphocytic leukemia (CLL) and certain types of small lymphocytic lymphoma . CLL is the most prevalent leu...
- Indication
本品与阿扎胞苷联合用于治疗因合并症不适合接受强诱导化疗，或者年龄75岁及以上的新诊断的成人急性髓系白血病患者。
- Associated Conditions
- Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Associated Therapies
- -
Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
- Conditions
- Grade 3a Follicular LymphomaRecurrent Marginal Zone LymphomaB-Cell Lymphoma, UnspecifiedGrade 2 Follicular LymphomaRefractory Burkitt LymphomaRefractory Diffuse Large B-Cell LymphomaTransformed Recurrent Non-Hodgkin LymphomaRecurrent Burkitt LymphomaRecurrent Diffuse Large B-Cell LymphomaRecurrent Follicular Lymphoma
- Interventions
- First Posted Date
- 2016-12-14
- Last Posted Date
- 2024-04-09
- Lead Sponsor
- Beth Christian
- Target Recruit Count
- 22
- Registration Number
- NCT02992522
- Locations
- 🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Combination of Obinutuzumab and Venetoclax in Relapsed or Refractory DLBCL
- Conditions
- Interventions
- First Posted Date
- 2016-12-09
- Last Posted Date
- 2022-02-16
- Lead Sponsor
- Arbeitsgemeinschaft medikamentoese Tumortherapie
- Target Recruit Count
- 22
- Registration Number
- NCT02987400
- Locations
- 🇦🇹
Universitätsklinik für Innere Med. III, PMU Salzburg, Salzburg, Austria
🇦🇹Medizinische Universität Innsbruck Univ.-Klinik für Innere Medizin V Hämatologie und Onkologie, Innsbruck, Austria
🇦🇹UK Graz: Universitätsklinik für Innere Medizin; Klinische Abteilung für Hämatologie, Graz, Austria
A Study Evaluating the Impact of Venetoclax on the Quality of Life for Subjects With Relapsed (Your Cancer Has Come Back) or Refractory (no Response to Previous Cancer Treatments) Chronic Lymphocytic Leukemia (CLL) While Receiving Venetoclax Monotherapy (a Single Agent).
- First Posted Date
- 2016-12-02
- Last Posted Date
- 2023-02-22
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 210
- Registration Number
- NCT02980731
- Locations
- 🇦🇺
St George Hospital /ID# 154212, Kogarah, New South Wales, Australia
🇦🇺Liverpool Hospital /ID# 154950, Liverpool, New South Wales, Australia
🇦🇺Gold coast University Hospital /ID# 150833, SouthPort, Queensland, Australia
A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2016-11-17
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 110
- Registration Number
- NCT02966756
- Locations
- 🇨🇳
Anhui Provincial Cancer Hospital /ID# 209458, Hefei, Anhui, China
🇨🇳The Second Hospital of Hebei Medical University /ID# 159143, Shijiazhuang, Hebei, China
🇨🇳West China Hospital, Sichuan University /ID# 156537, Chengdu, Sichuan, China
A Study Evaluating Venetoclax Alone and in Combination With Azacitidine in Participants With Relapsed/Refractory Myelodysplastic Syndromes (MDS)
- Conditions
- Interventions
- First Posted Date
- 2016-11-17
- Last Posted Date
- 2023-05-09
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 70
- Registration Number
- NCT02966782
- Locations
- 🇺🇸
Duplicate_University of Chicago /ID# 155364, Chicago, Illinois, United States
🇺🇸University of Massachusetts - Worcester /ID# 155366, Worcester, Massachusetts, United States
🇦🇺Royal Perth Hospital /ID# 155951, Perth, Western Australia, Australia
Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2016-11-06
- Last Posted Date
- 2024-05-21
- Lead Sponsor
- Georgetown University
- Target Recruit Count
- 24
- Registration Number
- NCT02956382
- Locations
- 🇺🇸
Seattle Cancer Care Alliance, Seattle, Washington, United States
🇺🇸John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸Georgetown Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States
A Study of Venetoclax and ABBV-838 Combination Therapy With Dexamethasone in Participants With Multiple Myeloma Whose Cancer Has Come Back or Had No Response to Recent Cancer Treatment
- Conditions
- Interventions
- First Posted Date
- 2016-11-01
- Last Posted Date
- 2017-06-05
- Lead Sponsor
- AbbVie
- Registration Number
- NCT02951117
- Locations
- 🇦🇺
St Vincent´s Hospital /ID# 153022, Darlinghurst, Australia
🇦🇺The Alfred Hospital /ID# 150202, Prahran, Australia
🇦🇺St. Vincents Hospital Melbourne /ID# 157925, Fitzroy, Australia
Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab + Venetoclax (RVe) Versus Obinutuzumab (GA101) + Venetoclax (GVe) Versus Obinutuzumab + Ibrutinib + Venetoclax (GIVe) in Fit Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without Del(17p) or TP53 Mutation
- First Posted Date
- 2016-10-31
- Last Posted Date
- 2024-03-06
- Lead Sponsor
- German CLL Study Group
- Target Recruit Count
- 926
- Registration Number
- NCT02950051
- Locations
- 🇮🇱
Kaplan Medical Center, Rechovot, Israel
🇳🇱Canisius-Wilhelmina ZH, Nijmegen, Netherlands
🇳🇱Antonius Ziekenhuis Sneek, Sneek, Netherlands
A Study Evaluating Venetoclax in Combination With Azacitidine in Participants With Treatment-Naïve Higher-Risk Myelodysplastic Syndromes (MDS)
- Conditions
- Interventions
- First Posted Date
- 2016-10-24
- Last Posted Date
- 2024-07-05
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 129
- Registration Number
- NCT02942290
- Locations
- 🇺🇸
Tufts Medical Center /ID# 153672, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute /ID# 152735, Boston, Massachusetts, United States
🇺🇸University of Arizona Cancer Center - North Campus /ID# 154155, Tucson, Arizona, United States
Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL)
- Conditions
- Interventions
- First Posted Date
- 2016-09-22
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Pharmacyclics LLC.
- Target Recruit Count
- 323
- Registration Number
- NCT02910583
- Locations
- 🇺🇸
University of Pennsylvania /ID# 1142-0069, Philadelphia, Pennsylvania, United States
🇦🇺St Vincent's Hospital Melbourne /ID# 1142-0501, Fitzroy, Victoria, Australia
🇺🇸Tennessee Oncology - Chattanooga /ID# 1142-0123, Chattanooga, Tennessee, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.